However, a phase II clinical trial evaluating the safety and efficacy of lapatinib in treatment refractory stage IV melanoma patients carrying ERBB4 mutations (NCT01264081) was terminated with 30/34 patients failing to complete the trial. The gene discussed is ERBB4; the disease is melanoma.